312 related articles for article (PubMed ID: 11731422)
21. Increased placental iron regulatory protein-1 expression in diabetic pregnancies complicated by fetal iron deficiency.
Georgieff MK; Berry SA; Wobken JD; Leibold EA
Placenta; 1999 Jan; 20(1):87-93. PubMed ID: 9950149
[TBL] [Abstract][Full Text] [Related]
22. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
23. Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis.
Kotamraju S; Kalivendi SV; Konorev E; Chitambar CR; Joseph J; Kalyanaraman B
Methods Enzymol; 2004; 378():362-82. PubMed ID: 15038980
[No Abstract] [Full Text] [Related]
24. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
25. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
[TBL] [Abstract][Full Text] [Related]
26. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
27. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
28. Regulation of ferritin synthesis and iron regulatory protein 1 by oxygen in mouse peritoneal macrophages.
Kuriyama-Matsumura K; Sato H; Yamaguchi M; Bannai S
Biochem Biophys Res Commun; 1998 Aug; 249(1):241-6. PubMed ID: 9705865
[TBL] [Abstract][Full Text] [Related]
29. Molecular pharmacology of the interaction of anthracyclines with iron.
Xu X; Persson HL; Richardson DR
Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model.
Panjrath GS; Patel V; Valdiviezo CI; Narula N; Narula J; Jain D
J Am Coll Cardiol; 2007 Jun; 49(25):2457-64. PubMed ID: 17599610
[TBL] [Abstract][Full Text] [Related]
31. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
32. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin.
Corna G; Santambrogio P; Minotti G; Cairo G
J Biol Chem; 2004 Apr; 279(14):13738-45. PubMed ID: 14739295
[TBL] [Abstract][Full Text] [Related]
34. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.
Minotti G; Mancuso C; Frustaci A; Mordente A; Santini SA; Calafiore AM; Liberi G; Gentiloni N
J Clin Invest; 1996 Aug; 98(3):650-61. PubMed ID: 8698856
[TBL] [Abstract][Full Text] [Related]
35. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
36. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats.
Zordoky BN; Anwar-Mohamed A; Aboutabl ME; El-Kadi AO
Toxicol Appl Pharmacol; 2010 Jan; 242(1):38-46. PubMed ID: 19796650
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
[TBL] [Abstract][Full Text] [Related]
38. Iron-dependent turnover of IRP-1/c-aconitase in kidney cells.
Liu Y; Templeton DM
Metallomics; 2015 May; 7(5):766-75. PubMed ID: 25652229
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine.
Abd El-Gawad HM; El-Sawalhi MM
J Biochem Mol Toxicol; 2004; 18(2):69-77. PubMed ID: 15122648
[TBL] [Abstract][Full Text] [Related]
40. IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice.
Corna G; Galy B; Hentze MW; Cairo G
J Mol Med (Berl); 2006 Jul; 84(7):551-60. PubMed ID: 16770644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
